Journal of Drug Abuse Open Access

  • ISSN: 2471-853X
  • Journal h-index: 10
  • Journal CiteScore: 1.81
  • Journal Impact Factor: 1.92
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +32 25889658

Guan Xuehao

Shandong Provincial Medicine and Health Key Laboratory of Clinical Anesthesia, Department of Anesthesiology, Weifang Medical University, Weifang, China

Publications
  • Review Article   
    Sacubitril/valsartan: a new antihypertensive drug in the future?
    Author(s): Guan Xuehao, Zhang Rui, Zhang Guangfang, Wang Jian, Wang Shuguang, Liu Baoshan* and Zhang Aiyuan*

    Hypertension is one of the leading epidemic factors of cardiovascular and cerebrovascular disease around the world. Many researchers have found that Sacubitril/Valsartan, the single angiotensin receptor-neprilysin inhibitor, played a critical role in lowering hypertension. However, Sacubitril/Valsartan’s indications and usage for hypertension has not been accepted in the world, except for China. The mechanism of Sacubitril/Valsartan’s antihypertensive effect is clear, including inhibiting renin-angiotensin system and reducing natriuretic peptides’ degradation. In this article, we retrieved and reviewed all clinical studies that explored the effect of Sacubitril/Valsartan or its safety in the treatment of hypertension patients. Most studies concluded that in comparison with traditional antihypertensive drugs (mainly including angiotensin receptor .. View More»

    DOI: 10.36648/2471-853X.22.8.111

    Abstract HTML PDF